Global distribution mechanisms for biotech products

Introduction

Global distribution mechanisms for biotechnology products refer to the legal, commercial and regulatory systems through which biotechnology-related products are manufactured, transported, marketed and supplied across international borders. These products include vaccines, diagnostic kits, genetically modified seeds, biological medicines, cell-based therapies, agricultural biotechnology products and other products developed through biological research.

The distribution of biotechnology products is more complicated than ordinary commercial trade because these products may involve living organisms, biological materials, temperature-sensitive substances and specialised storage requirements. Their international movement must comply with product safety standards, intellectual property laws, customs regulations, environmental requirements and public-health obligations.

The primary objective of global distribution governance is to ensure that biotechnology products reach international markets safely, efficiently and fairly.

International legal framework

1. World Trade Organization agreements

The World Trade Organization (WTO) provides important rules governing international trade in biotechnology products.

The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement) regulates measures intended to protect human, animal and plant health. Countries may impose appropriate safety requirements, but these measures should be based on scientific principles and should not create unjustified trade restrictions.

The Agreement on Technical Barriers to Trade (TBT Agreement) addresses technical regulations, standards and conformity-assessment procedures. It is relevant to biotechnology product labelling, quality standards and technical certification.

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) establishes minimum intellectual property protection standards. It influences the international distribution of patented biotechnology products, including medicines and agricultural innovations.

2. Cartagena Protocol on Biosafety, 2000

The Cartagena Protocol to the Convention on Biological Diversity regulates the safe handling, transport and use of living modified organisms resulting from modern biotechnology that may adversely affect biodiversity.

Its Advance Informed Agreement procedure applies to certain first intentional transboundary movements of living modified organisms intended for introduction into the environment. The Protocol also establishes documentation and information-sharing requirements.

It does not automatically apply to every biotechnology product. Its scope depends on the nature and intended use of the organism.

3. Convention on Biological Diversity

The Convention on Biological Diversity provides principles concerning conservation, sustainable use and fair sharing of benefits arising from the utilisation of genetic resources.

These principles may influence international biotechnology supply chains where products depend on biological resources obtained from other countries.

Major global distribution mechanisms

1. Direct international distribution

Biotechnology manufacturers may directly export products to foreign distributors, hospitals, research institutions or agricultural suppliers. This model provides greater control over product quality, pricing and regulatory compliance.

However, manufacturers must obtain the necessary approvals in destination countries and comply with import requirements.

2. Distributor and licensing arrangements

Companies frequently appoint authorised international distributors to market and supply biotechnology products. Licensing agreements may permit foreign companies to manufacture or distribute products using patented technologies.

These arrangements can expand international availability while requiring contractual safeguards concerning quality, confidentiality, intellectual property and regulatory responsibilities.

3. International procurement mechanisms

Organisations such as UNICEF and Gavi, the Vaccine Alliance, support the procurement and distribution of vaccines and other health-related products. International procurement mechanisms can improve access, particularly in developing countries.

The World Health Organization's prequalification programme also helps assess the quality, safety and efficacy of certain medical products intended for international procurement.

4. Cold-chain distribution

Vaccines, biological medicines and certain cell-based products require controlled storage and transportation conditions. Cold-chain systems use specialised packaging, temperature monitoring and documented handling procedures.

Failure to maintain required conditions may affect product quality and patient safety.

5. Digital and technology-based distribution

Digital platforms support product traceability, inventory management, regulatory documentation and supply-chain monitoring. However, digital distribution systems must protect confidential commercial information and personal health data.

Indian legal and regulatory framework

India regulates biotechnology product distribution through several laws depending on the nature of the product.

The Drugs and Cosmetics Act, 1940, and applicable rules regulate the import, manufacture, sale and distribution of drugs and certain biological products. The Central Drugs Standard Control Organisation (CDSCO) performs important regulatory functions relating to drug approvals and import permissions.

The Foreign Trade (Development and Regulation) Act, 1992, provides the statutory foundation for India's foreign-trade regulatory framework. The Directorate General of Foreign Trade (DGFT) administers the Foreign Trade Policy and relevant import-export requirements.

The Environment (Protection) Act, 1986, and the 1989 Rules concerning hazardous microorganisms and genetically engineered organisms regulate specified activities involving genetically engineered biological materials.

The Food Safety and Standards Act, 2006, applies to biotechnology-derived food products falling within its regulatory scope. Food businesses must comply with applicable safety, licensing, labelling and import requirements.

Furthermore, the Biological Diversity Act, 2002, as amended in 2023, is relevant to access and benefit-sharing obligations involving biological resources and associated knowledge, subject to its statutory scope and exemptions.

Relevant case laws

Although Indian courts have not developed a specialised body of case law exclusively concerning global distribution mechanisms for biotechnology products, several decisions establish relevant legal principles.

1. Novartis AG v. Union of India (2013)

The Supreme Court interpreted Section 3(d) of the Patents Act, 1970, concerning patentability of pharmaceutical inventions. The judgment demonstrates the relationship between intellectual property protection, pharmaceutical innovation and public access to medicines.

2. Bayer Corporation v. Union of India (2014)

The Delhi High Court considered issues relating to compulsory licensing and the legal framework governing pharmaceutical patents. The decision is relevant to discussions about balancing patent rights with access to essential medicines.

3. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court recognised the precautionary principle and polluter-pays principle as important elements of Indian environmental law. These principles are relevant when distributing biotechnology products that may create environmental risks.

4. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

The Supreme Court considered a dispute involving genetically modified cotton technology and patent-related rights. The judgment illustrates the importance of intellectual property arrangements in the commercialisation and distribution of agricultural biotechnology products. The matter was remanded, and the decision should not be treated as a biosafety approval.

5. Divya Pharmacy v. Union of India (2018)

The Uttarakhand High Court examined benefit-sharing obligations under the Biological Diversity Act. The decision is relevant to questions concerning commercial utilisation of biological resources and equitable distribution of benefits.

Major challenges in global distribution

Global biotechnology distribution faces several legal and operational difficulties:

Different national approval and licensing requirements.

High transportation and specialised storage costs.

Intellectual property disputes and licensing restrictions.

Unequal access between developed and developing countries.

Customs delays and inconsistent product classification.

Environmental risks involving certain living modified organisms.

Counterfeit products and inadequate supply-chain traceability.

Recommendations and conclusion

Governments should improve international regulatory cooperation, harmonise appropriate quality standards and strengthen product-traceability systems. Biotechnology companies should maintain transparent distribution agreements, comply with destination-country approvals and establish reliable storage and transportation arrangements.

International organisations should also encourage fair procurement systems and affordable access to essential biotechnology products.

Global distribution mechanisms are essential for translating biotechnology research into practical healthcare, agricultural and industrial benefits. However, successful distribution requires more than commercial efficiency. It must balance international trade, intellectual property protection, environmental safety, public health and equitable access. A coordinated legal framework can ensure that biotechnology products are distributed responsibly while supporting innovation and international cooperation.